Tuberculosis (TB) remains a global health crisis with drug-resistant strains posing a growing
threat. Traditional antibiotics face limitations in treatment length and resistance
development. A revolutionary approach called Host-Directed Therapy (HDT) is emerging.HDT
doesn't target the bacteria directly but instead strengthens the body's own defenses against
TB. Imagine boosting the immune system's ability to fight the infection and prevent its
persistence. This not only tackles existing TB strains but also holds promise for reducing the
risk of relapse and the formation of drug-resistant bacteria.Early research on HDT is
encouraging. By unlocking the body's natural TB-fighting potential this approach could
revolutionize TB treatment offering a much-needed weapon in the fight against this devastating
disease.
